A Collaborative Study of a Proposed International Standard for Tissue Plasminogen Activator (t-PA)^[*]

Summary

An international collaborative study involving seven laboratories was undertaken to assess which of three lyophilised preparations might serve as an International Standard (I.S.) for tissue plasminogen activator (t-PA). Two of the preparations were isolates from human melanoma cell cultures while one was of pig heart origin. A clot lysis assay was used by all participants in the study.

The data suggested that both preparations of human cell origin were comparable, in that their log dose-response lines were parallel, while that of the porcine preparation was not. Accelerated degradation studies indicated that one melanoma extract (denoted 83/517) was more stable than the other and it was decided to recommend preparation 83/517 as the standard for t-PA. The International Committee for Thrombosis and Haemostasis (Stockholm 1983) has recommended the use of this material as a standard and it has been established by the Expert Committee on Biological Standardization of the World Health Organization as the International, Standard for tissue plasminogen activator, with an assigned potency of 1000 International Units per ampoule.

Key words

Tissue plasminogen activator (t-PA) - International Standard - Clot lysis assay

^* This study was conducted in cooperation with the Fibrinolysis Subcommittee of the International Committee on Thrombosis and Haemostasis

• References

• 1 International Committee for Thrombosis and Haemostasis (XXVIIIth Meeting). Fibrinolysis Subcommittee; Bergamo, Italy: 07/1983
• 2 Gaffney PJ. Molecular and functional condition of plasma fibrinogen during thrombolytic therapy with streptokinase (SK). Thromb Res 1973; 2: 105-114
• 3 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 4 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Yelverton E, Seeburg PH, Heyneker HL, Goedde DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E.coli. Nature 1983; 301: 214-221
• 5 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin J Biol Chem 1982; 257: 2912-2919
• 6 Matsuo O, Rijken DC, Collen D. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolism. Nature 1981; 291: 590-591
• 7 Weimar W, Stibbe J, Van Seyen AJ, Billiau A, De Somer P, Collen D. Specific lysis of an ileofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981; 2: 1018-1020
• 8 Juhan-Vague I, Moerman B, De Cock F, Ailiaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
• 9 Gaffney PJ, Templeman JH, Curtis AD, Campbell PJ. The stability of tissue plasminogen activator (t-PA). Thromb Haemostas 1983; 50: 650-651
• 10 Campbell PJ. International biological standards and reference preparations. I: Preparation and presentation of materials to serve as standards and reference preparations. J Biol Stand 1974; 2: 249-258
• 11 Philo RD, Gaffney PJ. Plasmin potency estimates: influence of the substrate used in assay. Thromb Haemostas 1981; 45: 107-109
• 12 Finney DJ. Statistical Method in Biological Assay. 3. ed Griffin; London: 1978
• 13 Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KA, De Geest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984; 310: 609-613